The effect of captopril on renal function in patients during the first cis-diamminedichloroplatinum II infusion

Offerman, Jjg; Sleijfer, Dirk; Mulder, Nanno; Meijer, S; Koops, Heimen Schraffordt; Donker, A. J. M.

doi:10.1007/bf00258130

Cited by 10 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an earlier study we postulated the hypothesis of the influence of CDDP on renal function through a stimulation of the intrarenal prostaglandin synthesis and thus an activation of the renin-angiotensin system [5], as has been described for mercuric chloride [16] and uranyl nitrate [17], Captopril. an angiotensin I converting enzyme inhibitor, indeed appeared to be able to prevent the initial decrease in ERPF during the first course of CDDP [5]. Apparently captopril also prevented some of the decrease in ERPF on day 10 in this study.…”

Section: Resultsmentioning

confidence: 99%

“…an angiotensin-I-converting enzyme inhibitor given concomitantly with CDDP in order to prevent CDDP-induced nephro toxicity, was found to prevent the initial decrease in effec tive renal plasma flow (ERPF) [5]. It seemed worthwhile to investigate the possibility that captopril might also prevent the fall in glomerular filtration rate (GFR) later on.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Captopril on cis-Diamminedichloroplatinum-Induced Renal Toxicity

Offerman¹,

Mulder²,

Sleijfer³

et al. 1985

Am J Nephrol

View full text Add to dashboard Cite

Renal function studies were performed in 18 patients with nonseminomatous testicular cancer during four platinum-containing chemotherapy courses. The first 9 patients received chemotherapy alone, the second 9 also captopril, an angiotensin I converting enzyme inhibitor, in order to prevent cis-diamminedichloroplatinum-induced nephrotoxicity. In the first group a decrease in glomerular filtration rate, that was preceded by a fall in effective renal plasma flow, was observed. In the second group, captopril was able to prevent the initial decrease in effective renal plasma flow, but failed to prevent the ultimate decrease in glomerular filtration rate.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Influence of Captopril on cis-Diamminedichloroplatinum-Induced Renal Toxicity

Offerman¹,

Mulder²,

Sleijfer³

et al. 1985

Am J Nephrol

View full text Add to dashboard Cite

show abstract

The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man

Sleijfer¹,

Offerman²,

Mulder³

et al. 1987

Cancer

View full text Add to dashboard Cite

Nine patients (Group A) with histologically proven, nonseminomatous testicular cancer were treated with cisplatin (CDDP) according to the Einhorn regimen. Renal function studies including the measurement of the effective renal plasma flow (ERPF) and the glomerular filtration rate (GFR) were performed prior to the chemotherapy and then after treatment on days 10 and 21 of the first course. In order to prevent CDDP-induced nephrotoxicity, verapamil (a calcium entry blocker) and cimetidine were given along with CDDP. The results were compared with others from another group of nine patients (Group B) treated with CDDP, but without verapamil and cimetidine. In Group A there was much less of a decrease in ERPF as compared to Group B on day 21. In addition, the decrease in GFR on days 10 and 21 was totally prevented in the verapamil- and cimetidine-treated group.

show abstract

Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration

Dulberg¹,

Molepo²,

Mikhael³

et al. 1994

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

The objective of this study was to determine factors that affect cisplatin concentrations in human kidney cortex. We used flameless atomic absorption spectrophotometry to assay platinum in autopsy specimens of kidney cortex obtained from 83 cisplatin-treated patients. Concentrations were correlated with pretreatment factors and treatment conditions using univariate nonparametric statistics. Hierarchical stepwise multiple regression analyses of transformed (to normalize) data were then used to assess which factors were most important, controlling for other factors. Kidney-cortex platinum concentrations varied from 0 to 14.8 micrograms/g (median, 2.04 micrograms/g). The cumulative lifetime dose of cisplatin ranged from 10 to 1120 mg/m2 (median, 112 mg/m2). The time from the last cisplatin dose to death was < 1-609 days (median, 38 days). According to univariate statistics, factors that correlated (P < 0.05) with kidney-cortex platinum concentrations were the cisplatin dose per course, the pretreatment serum urea level, metoclopramide use (positive correlations), the time from the last cisplatin treatment to death, and the pretreatment serum albumin value (negative correlations). Factors that approached significance (0.05 < or = P < or = 0.10) were a history of hypertension, hyperbilirubinemia (positive), the serum calcium level, and phenytoin use (negative). In the multiple regression analysis, after controlling for the cisplatin dose per course and the time from the last treatment to death, only concurrent metoclopramide and phenytoin use entered the model. The hydration volume did not affect corrected kidney-cortex or kidney-medulla platinum concentrations. The following conclusions were reached: (1) it may be feasible to use lower hydration volumes than those used routinely, (2) any effect of hydration volume on cisplatin nephrotoxicity may not be mediated via a reduction in kidney-cortex platinum concentrations, (3) higher cisplatin doses might be tolerated with new 5-hydroxytryptamine-3 (5HT-3) antiemetics than were tolerated with metoclopramide, and (4) phenytoin should be tested for its ability to reduce cisplatin nephrotoxicity.

show abstract

The effect of captopril on renal function in patients during the first cis-diamminedichloroplatinum II infusion

Cited by 10 publications

References 12 publications

Influence of Captopril on cis-Diamminedichloroplatinum-Induced Renal Toxicity

Influence of Captopril on cis-Diamminedichloroplatinum-Induced Renal Toxicity

The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man

Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration

Contact Info

Product

Resources

About